At the time of presentation, most ovarian cancers are no longer dependent on single genetic determinants for growth and/or survival. Targeted therapies used as single agents will not work in this disease and thus second site lethality screens will help identify critical pathways to target in combination with novel biologics. Our objectives are to take genes obtained through our synthetic lethal siRNA screens, and use them to map the sensitization network for targeted therapeutics relevant to EOC, and design meaningful combinations of siRNAs with drugs, or drugs with drugs, that can be rapidly translated to the clinic. We have used RNAi approaches to identify candidates that selectively enhance killing by the Src-targeting agent, dasatinib (also known as BMS-354825, Sprycel""""""""). Mapping the pattern of hits back to the network map revealed suggestive clusters of closely interacting proteins, implying identification of key survival nodes. The three Aims proposed will systematically develop our preliminary studies to identify productive targets of co-inhibition, with the ultimate goal of identifying new drug combinations that will greatly enhance the treatment of women with EOC. Hence, Aims 1 &2 are designed to apply a series of in vitro filters to help prioritize selection of the optimal combination of proteins to target using clinically relevant therapies in animal models. Specifically, Aim 1 will refine our high-value list of validated dasatinib-sensitizing siRNAs by screening a set of EOC cell lines and primary cultures generated from ascites obtained from patient with ovarian cancer and cluster these sensitizing genes into coordinated groups based on network modeling, in vitro drug-drug synergy studies, and functional studies to be completed in this Aim.
In Aim 2, we will explore the expression patterns of proteins and transcripts for the refined hits identified in Aim 1 in patient samples to assess their pathological and clinical relevance.
In Aim 3, for the highest priority hits we will conduct drug pharmacokinetic and toxicity studies in animals using drug-drug combinations evaluated at various ratios as dictated by our in vitro synergy data. We will identify optimal dosage regimens and evaluate their therapeutic efficacy in xenograft animal models. For hits lacking clinically developed agents, we will perform siRNA-drug combinations in the animal models. We believe that this cutting-edge approach will yield a paradigm that can subsequently be applied for multiple therapeutic applications.

Public Health Relevance

The studies proposed offer an unprecedented opportunity to employ a functional approach in designing combination therapies that can be applied to improve ovarian cancer treatment outcomes with contemporary agents such as dasatinib, with or without the front line chemotherapeutic agents, platinum and paclitaxel. They will also provide valuable preclinical resources regarding drug safety and dosage regimen to help design future clinical trials with combination therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA140323-05
Application #
8607904
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Arya, Suresh
Project Start
2010-04-01
Project End
2015-01-31
Budget Start
2014-04-15
Budget End
2015-01-31
Support Year
5
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Kansas
Department
Pathology
Type
Schools of Medicine
DUNS #
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Kwon, Youngjoo; Godwin, Andrew K (2017) Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer. Reprod Sci 24:494-501
Lecarpentier, Julie; Silvestri, Valentina; Kuchenbaecker, Karoline B et al. (2017) Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol 35:2240-2250
Walker, Logan C; Marquart, Louise; Pearson, John F et al. (2017) Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet 25:432-438
Do, Thuy-Vy; Hirst, Jeff; Hyter, Stephen et al. (2017) Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. Oncotarget 8:50376-50392
Milne, Roger L (see original citation for additional authors) (2017) Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet 49:1767-1778
Crow, Jennifer; Atay, Safinur; Banskota, Samagya et al. (2017) Exosomes as mediators of platinum resistance in ovarian cancer. Oncotarget 8:11917-11936
Rebbeck, Timothy R; Friebel, Tara M; Mitra, Nandita et al. (2016) Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res 18:112
Lawrenson, Kate (see original citation for additional authors) (2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 (see original citation for additional authors) (2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401
Silvestri, Valentina; Barrowdale, Daniel; Mulligan, Anna Marie et al. (2016) Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 18:15

Showing the most recent 10 out of 70 publications